Physician profile
Ted D Chung
NPI 1639148166
$5,772.46
in general payments reported to CMS, 2019-2025
32 companies · $275 in 2025
The $275 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,468 · 2020: $389 · 2021: $709 · 2022: $1,255 · 2023: $1,305 · 2024: $373 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,368 · Travel and Lodging: $485 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,368.14 |
| Travel and Lodging | $484.98 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,620.11 | 2019-2025 | Xtandi, Myrbetriq, Veozah |
| Neotract INC. | $1,132.97 | 2019-2020 | |
| Antares Pharma, INC. | $600.84 | 2021-2023 | Xyosted, Tlando, Nocdurna |
| Teleflex LLC | $533.03 | 2021-2023 | Urolift |
| Sumitomo Pharma America, INC. | $383.74 | 2023-2025 | Gemtesa, Orgovyx |
| Tolmar Pharmaceuticals, INC. | $274.49 | 2021-2022 | |
| Caldera Medical, INC | $138.57 | 2021-2023 | Desara |
| Pfizer INC. | $135.37 | 2019-2023 | |
| Procept Biorobotics Corporation | $110.87 | 2024-2025 | Aquabeam System |
| Myovant Sciences INC. | $106.94 | 2021-2022 | |
| Janssen Biotech, INC. | $105.38 | 2019-2023 | Erleada |
| Urovant Sciences INC | $81.48 | 2021-2022 | |
| Tolmar, INC. | $63.05 | 2023-2024 | |
| Boston Scientific Corporation | $61.61 | 2020-2021 | |
| Abc Home Medical Supply, INC. | $59.93 | 2022-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $35.83 | 2019 | |
| Coloplast Corp | $35.16 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $30.84 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $25.80 | 2019 | |
| Halozyme INC | $24.61 | 2023 | |
| Blue Earth Diagnostics | $23.79 | 2021 | |
| Hollister Incorporated | $21.48 | 2024 | Vapro Pocket |
| Abbvie INC. | $20.32 | 2025 | |
| Olympus America INC. | $20.12 | 2025 | Bovie |
| Novo Nordisk INC | $19.59 | 2019 | |
| Progenics Pharmaceuticals, INC. | $18.83 | 2025 | |
| Ethicon US, LLC | $16.16 | 2019 | |
| 180 Medical, INC. | $16.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.26 | 2022 | |
| Convatec INC. | $14.96 | 2022 | |
| Endo Pharmaceuticals INC. | $13.32 | 2022 | |
| Urogen Pharma, INC. | $12.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ted Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.